The estimated Net Worth of James R Sulat is at least $2.31 Million dollars as of 14 March 2023. Mr. Sulat owns over 30,000 units of AMAG Pharmaceuticals stock worth over $2,063,825 and over the last 16 years he sold AMAG stock worth over $0. In addition, he makes $242,174 as Independent Director at AMAG Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Sulat AMAG stock SEC Form 4 insiders trading
James has made over 8 trades of the AMAG Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of AMAG stock worth $254,400 on 14 March 2023.
The largest trade he's ever made was buying 30,000 units of AMAG Pharmaceuticals stock on 14 March 2023 worth over $254,400. On average, James trades about 2,311 units every 130 days since 2008. As of 14 March 2023 he still owns at least 82,553 units of AMAG Pharmaceuticals stock.
You can see the complete history of Mr. Sulat stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Sulat biography
James R. Sulat serves as Independent Director of the Company. From 2009 to 2013, Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc. ("Maxygen"), a public biopharmaceutical company, and was a member of Maxygen's Board of Directors from 2003 to 2013. From 2005 until 2008, Mr. Sulat served in several roles for Memory Pharmaceuticals Corp. ("Memory"), including as President and Chief Executive Officer from 2005 to 2008, as Chief Financial Officer during 2008, and as a member of Memory's Board of Directors from 2005 to 2009. Mr. Sulat has served on the Board of Directors of Arch Therapeutics, Inc., a public medical device company, since August 2015. Mr. Sulat served as the Chairman of the Board of Directors for Momenta Pharmaceuticals, Inc., a public biotechnology company, and as a member of its Audit Committee and its Nomination and Corporate Governance Committee from 2008 to July 2019. Since 2005, Mr. Sulat has served on the Supervisory Board of Intercell AG and, its successor company, Valneva SE, both public European biotechnology companies, and currently serves as Chairman of its Audit Committee. Mr. Sulat served on the Board of Directors of Diadexus, Inc., a public diagnostics company, from January 2015 to June 2016 as well as Chairman of its Audit Committee and a member of its Nominating and Corporate Governance Committee. Mr. Sulat also served as a member of the Board of Directors for Tolero Pharmaceuticals, Inc., a private biopharmaceutical company, from April 2015 to January 2017, when it was acquired by Sumitomo Dainippon Pharma Co., Ltd. Mr. Sulat received his B.S. in Administrative Sciences from Yale University. He received his M.B.A. and his M.S. in Health Services Administration from Stanford University.
What is the salary of James Sulat?
As the Independent Director of AMAG Pharmaceuticals, the total compensation of James Sulat at AMAG Pharmaceuticals is $242,174. There are 7 executives at AMAG Pharmaceuticals getting paid more, with Joseph Vittiglio having the highest compensation of $1,411,860.
How old is James Sulat?
James Sulat is 69, he's been the Independent Director of AMAG Pharmaceuticals since 2014. There are 2 older and 10 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.
What's James Sulat's mailing address?
James's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Insiders trading at AMAG Pharmaceuticals
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
What does AMAG Pharmaceuticals do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
What does AMAG Pharmaceuticals's logo look like?
Complete history of Mr. Sulat stock trades at AMAG Pharmaceuticals, Codexis, Momenta Pharmaceuticals, Mallinckrodt Plc, and Exicure Inc
AMAG Pharmaceuticals executives and stock owners
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Joseph Vittiglio,
Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer -
Anthony Casciano,
Chief Operating Officer, Executive Vice President and Chief Commercial Officer -
Gino Santini,
Independent Chairman of the Board -
Kathrine O'Brien,
Independent Director -
Anne Phillips,
Independent Director -
Davey Scoon,
Independent Director -
John Fallon,
Independent Director -
James Sulat,
Independent Director -
David Johnson,
Independent Director -
Paul Fonteyne,
Independent Director -
Linda Lennox,
Vice President - Investor Relations and Corporate Communications -
Nancy Griffith,
Vice President - Scientific Communications And Medical Operations -
Kelly Schick,
Chief Human Resource Officer, Senior Vice President -
Brian Piekos,
Chief Financial Officer -
Scott Myers,
President, Chief Executive Officer, Director -
Barbara Deptula,
Director -
Brian P Kelley,
Director -
Lesley Russell,
Director -
Robert J Perez,
Director -
Edward H Myles,
COO & CFO -
William K Heiden,
President & CEO -
Nicholas Grund,
Chief Commercial Officer -
Elizabeth Scott Bolgiano,
Chief Human Resources Officer -
Partners Lp Caligan,
10% owner -
Julie Krop,
Chief Medical Officer -
James Alan Butcher,
EVP, Chief Business Officer -
Capital Management Lp Camber,
-
Capital, Llc Armistice Capi...,
-
Kenneth H Wilson,
SVP, Sales and Marketing -
Geoffrey Crouse,
EVP -
Edward P. Jordan,
SVP, Sales and Marketing -
Scott B Townsend,
SVP, General Counsel -
Capital Partners Gp, L.L.C....,
-
Steven Caffe,
SVP, Ch. Dev. and Reg. Officer -
Ron Zwanziger,
Director -
Michael Narachi,
Director -
Sheldon L Bloch,
Director -
Christopher G White,
Chief Business Officer and SVP -
Jerome M Lewis,
VP of Scientific Operations -
David Arkowitz,
CFO & Chief Business Officer -
Jerome Goldstein,
CEO and Treasurer -
Ricardo Zayas,
Sr. Vice President, Operations -
Mark B Skaletsky,
Director -
Silva Rajiv De,
Director -
Gary J Zieziula,
EVP, Chief Commercial Officer -
Michael D Loberg,
Director -
Frank E Thomas,
President & COO -
Michael N Avallone,
VP-Finance and CFO -
Scott A Holmes,
Chief Accounting Officer -
Joseph Vincent Bonventre,
Director -
Brian Jg Pereira,
President and CEO -
Greg Madison,
EVP, Chief Commercial Officer -
Theodore I Steinman,
Director -
Edward B Roberts,
Director -
Timothy G Healey,
SVP-Commercial Operations -
Lee F Md Ph D Allen,
CMO & SVP Clinical Dev. -
Joseph L Farmer,
Gen Counsel & VP Legal Affairs -
Louis Md Brenner,
Senior Vice President